中国医学前沿杂志（电子版）Issue(7)：51-54,4.
康莱特辅助化疗对晚期非小细胞肺癌患者生存期的影响
Survival impact of Kanglaite adjuvant chemotherapy in advanced non-small cell lung cancer
毛良平 1孙锎 1张萍1
作者信息
- 1. 重庆三峡中心医院 呼吸内科，重庆 404000
- 折叠
摘要
Abstract
Objective To explore survival impact of Kanglaite adjuvant chemotherapy in advanced non-small cell lung cancer. Method 126 patients with advanced non-small cell cancer patients were randomly divided into observation group and control group, each group contained 63 cases, the control group treated with chemotherapy, and the observation group were treated with chemotherapy combined Kanglaite, recently efifcacy were observed and survival were followed-up. Result The effective rate was 47.6%in the observation group, and that was 20.6%in the control group, the 1-year survival rate was 68.3%and 49.2%in the observation group and the control group, the 2-year survival rate was 36.5%and 14.3%in the observation group and the control group, (P<0.05), the average survival period of observation group and control group was (689.4±164.1) days and (427.8±148.3) days with least 24 months followed-up, the median survival time was 568 days and 379 days in the observation group and the control group. Conclusion Kanglaite adjuvant chemotherapy can enhance the short-term efifcacy of non-small cell lung cance and two years survival rate.关键词
康莱特/化疗/晚期非小细胞肺癌/生存期Key words
Kanglaite/Chemotherapy/Advanced non-small cell lung cancer/Survival引用本文复制引用
毛良平,孙锎,张萍..康莱特辅助化疗对晚期非小细胞肺癌患者生存期的影响[J].中国医学前沿杂志（电子版）,2014,(7):51-54,4.
